0001214659-18-001631.txt : 20180227
0001214659-18-001631.hdr.sgml : 20180227
20180227180014
ACCESSION NUMBER: 0001214659-18-001631
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180223
FILED AS OF DATE: 20180227
DATE AS OF CHANGE: 20180227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BAUM CHARLES M
CENTRAL INDEX KEY: 0001579824
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35921
FILM NUMBER: 18646869
MAIL ADDRESS:
STREET 1: C/O MIRATI THERAPEUTICS INC.
STREET 2: 9393 TOWNE CENTRE DRIVE, STE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mirati Therapeutics, Inc.
CENTRAL INDEX KEY: 0001576263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462693615
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-332-3410
MAIL ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
marketforms-41119.xml
PRIMARY DOCUMENT
X0306
4
2018-02-23
0001576263
Mirati Therapeutics, Inc.
MRTX
0001579824
BAUM CHARLES M
C/O MIRATI THERAPEUTICS INC.
9393 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO
CA
92121
true
true
false
false
President & CEO
Common Stock
2018-02-23
4
M
false
51810
8.5
A
100366
D
Common Stock
2018-02-23
4
S
false
40748
27.8922
D
59618
D
Common Stock
2018-02-23
4
S
false
11062
28.5578
D
50932
D
Common Stock
8.50
2018-02-23
4
M
false
51810
0
D
2020-07-16
Common Stock
51810
155430
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.
This transaction was executed in multiple trades at prices ranging from $27.45 to $28.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $28.45 to $28.725. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
20% of the shares subject to the stock option vested and became exercisable on the Date of Grant and 20% of the shares vested on each of the 1st 2nd, 3rd and 4th anniversaries of November 12, 2012. The options expire on July 16, 2020.
Includes 2,376 shares acquired under the ESPP Purchase on 11/30/17.
/s/ Vickie Reed, Attorney-in-Fact
2018-02-27